[email protected]

国际医学与数据杂志

International Journal of Medicine and Data

您当前位置:首页 > 精选文章

International Journal of Medicine and Data. 2022; 6: (7) ; 10.12208/j.ijmd.20220194 .

Clinical efficacy of Xuebijing combined with meropenem in the treatment of septic shock
血必净联合美罗培南治疗脓毒症休克的临床疗效

作者: 江怡 *, 胡海强, 谢勇

新余市中医院 江西新余

新余北湖医院 江西新余

*通讯作者: 江怡,单位:新余市中医院 江西新余;

引用本文: 江怡, 胡海强, 谢勇 血必净联合美罗培南治疗脓毒症休克的临床疗效[J]. 国际医学与数据杂志, 2022; 6: (7) : 123-125.
Published: 2022/12/30 14:52:01

摘要

目的 分析血必净联合美罗培南治疗脓毒症休克的临床疗效。方法 选择我院2020年1月-2022年1月脓毒症休克患者共50例,数字表随机分2组每组25例,对照组的患者给予美罗培南治疗,观察组在该基础上增加血必净。比较两组治疗前后患者炎症因子、总有效率、不良反应。结果 观察组治疗后患者炎症因子低于对照组,总有效率高于对照组,P<0.05。结论 美罗培南联合血必净对于脓毒症休克的治疗效果确切,可有效降低炎症状况,提高治疗效果。

关键词: 血必净;美罗培南;脓毒症休克;临床疗效

Abstract

Objective: To analyze the clinical efficacy of Xuebijing combined with meropenem in the treatment of septic shock.
Methods: A total of 50 patients with septic shock in our hospital from January 2020 to January 2022 were selected, and the digital table was randomly divided into 2 groups with 25 cases in each group. The patients in the control group were treated with meropenem, and the observation group increased on this basis. Blood must be clean. The inflammatory factors, total effective rate and adverse reactions were compared between the two groups before and after treatment.
Results: After treatment, the inflammatory factors in the observation group were lower than those in the control group, and the total effective rate was higher than that in the control group, P<0.05.
Conclusion  : Meropenem combined with Xuebijing has exact therapeutic effect on septic shock, can effectively reduce inflammation and improve the therapeutic effect.

Key words: Xuebijing; Meropenem; Septic shock; Clinical efficacy

参考文献 References

[1] 赵绍强. 美罗培南联合小剂量氢化可的松治疗急诊脓毒症休克的临床研究[J].内蒙古医学杂志,2020,52(01):54-55.

[2] 林翰锋. 参附注射液联合血必净注射液治疗脓毒症休克对炎症指标和血流动力学的临床影响[J]. 北方药学,2019,16(12):51-52.

[3] 钟景兴,许春燕,彭锦. 连续血液净化联合血必净注射液治疗脓毒症休克患者临床观察[J].内科,2019,14(03):361-363.

[4] 卓辉武,李海云,李静. 美罗培南联合头孢哌酮钠他唑巴坦钠治疗对脓毒症休克合并急性肾功能不全患者炎性因子、肾功能及免疫球蛋白的影响[J]. 中国处方药,2022,20(03):127-129.

[5] 何鸿志,郭壮波. 美罗培南联合小剂量糖皮质激素治疗脓毒症休克患者的效果观察[J]. 中国现代医生,2021,59(31):27-30.

[6] 安东. 美罗培南注射剂联合头咆哌酮钠舒巴坦钠注射剂治疗脓毒症休克合并肾功能不全的临床研究[J]. 吉林医学,2021,42(02):417-418.

[7] 朱虹,苏晓蕾,张妍,房开宇,韩世权. 美罗培南注射剂联合头孢哌酮钠舒巴坦钠注射剂治疗MICU脓毒症休克并肾功能不全的效果[J]. 中国医学创新,2021,18(04):65-69.

[8] 郝晓东. 美罗培南联合头孢哌酮钠舒巴坦钠治疗脓毒症休克合并肾功能不全患者的疗效及安全性[J]. 医疗装备,2020,33(23):75-76.

[9] 谭效斌,张莹,吴树全,董婷婷,陈丽君. 美罗培南联合常规治疗对脓毒症休克合并急性肾功能不全患者炎性因子、肾功能及免疫球蛋白的影响[J]. 现代生物医学进展,2020,20(19):3766-3769+3796.

[10] 郭帮卫. 乌司他丁联合血必净治疗重症脓毒症休克效果及安全性分析[J]. 实用中西医结合临床,2020,20(12):126-127.